Galderma's Relfydess™ receives European approval for use, expanding treatment options.

Galderma's Relfydess™ (RelabotulinumtoxinA) has received a positive decision for use in Europe, expanding its treatment options for patients. This marks a significant milestone for Galderma, which specializes in dermatology and aesthetics. The European Commission's positive decision follows the European Medicines Agency's Committee for Medicinal Products for Human Use's recommendation.